What is the price-to-earnings ratio of Stratec?
The price-earnings ratio of Stratec is currently 2.17.
Stratec P/S 2024
Stratec P/S
2.17
Ticker
SBS.DE
ISIN
DE000STRA555
WKN
STRA55
As of Sep 10, 2024, Stratec's P/S ratio stood at 2.17, a -19.03% change from the 2.68 P/S ratio recorded in the previous year.
The Stratec P/S history
Stratec Aktienanalyse
What does Stratec do?
The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Stratec's P/S Ratio
Stratec's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Stratec's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Stratec's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Stratec’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Stratec stock
How has the price-earnings ratio of Stratec changed compared to last year?
The price-to-earnings ratio of Stratec has increased by -19.03% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Stratec high compared to other companies?
Yes, the price-to-earnings ratio of Stratec is high compared to other companies.
How does an increase in the price-earnings ratio of Stratec affect the company?
An increase in the price-earnings ratio of Stratec would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Stratec affect the company?
A decrease in the price-earnings ratio of Stratec would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Stratec?
Some factors that influence the price-earnings ratio of Stratec are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Stratec pay?
Over the past 12 months, Stratec paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Stratec is expected to pay a dividend of 1.05 EUR.
What is the dividend yield of Stratec?
The current dividend yield of Stratec is .
When does Stratec pay dividends?
Stratec pays a quarterly dividend. This is distributed in the months of June, June, June, June.
How secure is the dividend of Stratec?
Stratec paid dividends every year for the past 0 years.
What is the dividend of Stratec?
For the upcoming 12 months, dividends amounting to 1.05 EUR are expected. This corresponds to a dividend yield of 2.62 %.
In which sector is Stratec located?
Stratec is assigned to the 'Health' sector.
Wann musste ich die Aktien von Stratec kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Stratec from 5/22/2024 amounting to 0.55 EUR, you needed to have the stock in your portfolio before the ex-date on 5/20/2024.
When did Stratec pay the last dividend?
The last dividend was paid out on 5/22/2024.
What was the dividend of Stratec in the year 2023?
In the year 2023, Stratec distributed 0.95 EUR as dividends.
In which currency does Stratec pay out the dividend?
The dividends of Stratec are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Stratec stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Stratec
Our stock analysis for Stratec Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stratec Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
